top of page

FTC Final Order with Baxter International and Claris Lifesciences Preserves U.S. Competition for the

Safi Bello

Federal Trade Commission press release ------- Following a public comment period, the Federal Trade Commission has approved a final order designed to remedy the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business. To learn more click on the picture below to read the release.

FTC Final Order with Baxter International and Claris Lifesciences Preserves U.S. Competition for the Injectable Drugs Intravenous Fluconazole and Intravenous Milrinone - Read More from FTC

 
 
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon

© 2025 Safi Bello A Girls How To Guide

bottom of page